APA (7th ed.) Citation

A, M., R, N., A, S., D, C., C, R., G, C., . . . LE, A. (2022). Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75(1), e403. https://doi.org/10.1093/cid/ciac014

Chicago Style (17th ed.) Citation

A, Marrone, et al. "Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 75, no. 1 (2022): e403. https://doi.org/10.1093/cid/ciac014.

MLA (9th ed.) Citation

A, Marrone, et al. "Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 75, no. 1, 2022, p. e403, https://doi.org/10.1093/cid/ciac014.